Status:

COMPLETED

LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)

Lead Sponsor:

Novartis Pharmaceuticals

Conditions:

Tumors With CDK4/6 Pathway Activation

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The purpose of this signal seeking study was to determine whether treatment with LEE011 demonstrates sufficient efficacy in CDK4/6 pathway activated solid tumors and/or hematologic malignancies to war...

Eligibility Criteria

Inclusion

  • Patient had a confirmed diagnosis of a select solid tumor (except breast cancer (however, triple negative was included), liposarcoma, CRPC, melanoma and teratoma) or hematological malignancy (except mantle cell lymphoma).
  • Patient must have been pre-identified as having a tumor with CDK4 amplification or mutation, CDK6 amplification or mutation, Cyclin D1 (CCND1) amplification, Cyclin D3 (CCND3) amplification, or p16 (CDKN2A) mutation
  • Patient had received at least one prior treatment for recurrent, metastatic and /or locally advanced disease and for whom no standard therapy options are anticipated to result in a durable remission.
  • Patient had progressive and measurable disease as per RECIST 1.1. or other appropriate hematological guidelines.
  • Patient had an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

Exclusion

  • Patients had received prior treatment with LEE011.
  • Patient had clinically significant resting bradycardia (heart rate \< 50 at rest), tachycardia (heart rate \> 90 at rest), PR interval \> 220 msec, QRS interval \> 109 msec, or QTcF \> 450 msec.
  • Patients had primary CNS tumor or CNS tumor involvement
  • Patient had received chemotherapy or anticancer therapy ≤ 4 weeks prior to starting study drug

Key Trial Info

Start Date :

August 25 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 17 2018

Estimated Enrollment :

106 Patients enrolled

Trial Details

Trial ID

NCT02187783

Start Date

August 25 2014

End Date

January 17 2018

Last Update

July 18 2019

Active Locations (61)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 16 (61 locations)

1

University of Alabama at Birmingham

Birmingham, Alabama, United States, 35249

2

Alaska Clinical Research

Anchorage, Alaska, United States, 99503

3

Arizona Oncology Associates Dept. Of Onc.

Phoenix, Arizona, United States

4

University of Arkansas/ Arkansas Cancer Research Center UA Medical Sciences

Little Rock, Arkansas, United States, 72205